STAT+: Exit of CDC’s acting director highlights agency’s lack of leader
Stat News • 2/15/2026
Summary
The exit of the CDC’s acting director is highlighting the agency’s lack of a leader. The absence of a Senate-confirmed leader is deepening the turmoil at the CDC.
Advertisement
Lindy Score Breakdown (V4.2)
48d
Age
1
Sources
from cluster
1143
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1143/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1143/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 47 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about Trump tariff plans, FDA’s OK for a Lilly obesity pill, and more
Stat News • 1 day ago
STAT+: Medicare Advantage plans win extra $18.6 billion as feds cut star ratings measures
Stat News • 1 day ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • Today
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 1 day ago
STAT+: NIH director’s invocation of Vannevar Bush’s legacy to promote Trump science policies sparks pushback
Stat News • 2 days ago
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 2 days ago
STAT+: NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along
Stat News • Today
STAT+: White House proposes 12% cut to federal health agencies in 2027 budget request
Stat News • Today
STAT+: Biotech investors’ plea to Trump, and a busy M&A week
Stat News • Today
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
Anti-Lindy Similar stories
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago